Alterity Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRNAF research report →
About the company
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy.
- CEO
- David A. Stamler
- IPO
- 2012
- Employees
- 9
- HQ
- Melbourne, VIC, AU
Price Chart
- Market Cap
- $11.96M
- P/E
- -9.35
- P/S
- 38.02
- P/B
- 2.51
- EV/EBITDA
- -4.81
- Div Yield
- 0.00%
- Gross Margin
- 96.82%
- Op Margin
- -525.58%
- Net Margin
- -380.65%
- ROE
- -30.19%
- ROIC
- -31.32%
- Revenue
- $5.44M · 35.32%
- Net Income
- $-12,147,828 · 36.48%
- EPS
- $-0.10 · 63.46%
- Op Income
- $-14,574,286
- FCF YoY
- 9.20%
- 52W High
- $0.69
- 52W Low
- $0.00
- 50D MA
- $0.06
- 200D MA
- $0.27
- Beta
- 4.81
- Avg Volume
- 176
AI snapshot
Six angles, distilled from the data.
The stock remains in a deep long-term downtrend, trading far below its 200-day average of 0.2744 after a 52-week range of 0.01 to 0.54. The setup is still speculative, with the recent regime anchored near the lower end of its yearly band rather than in a confirmed recovery trend.
Street sentiment is lightly constructive, with a Buy consensus and no recent rating changes or price-target revisions. The lack of fresh upgrades keeps the setup dependent on clinical progress and execution rather than a broader re-rating.
Earnings history has been weak, with a 0/8 beat rate and no evidence of consistent upside surprises. Shareholders should watch whether revenue growth and cash burn stay manageable, since estimates still point to losses through 2029 before a small profit is modeled in 2030.
No notable insider activity. With no recent transactions reported, there is no discretionary buying or selling signal to read into.
Profitability remains challenged despite very high gross margin of 97.5%, because operating losses and cash burn are still material. Revenue grew 74.6% year over year, but operating cash flow was -11.45 million and free cash flow was -11.45 million in fiscal 2025.
As a clinical-stage biotech, PRNAF trades on pipeline optionality rather than current earnings power, which leaves it more dependent on trial milestones than commercial peers. The valuation is still distressed versus the sector, with a tiny market cap and no meaningful earnings support.
Our PRNAF coverage
Recent articles, reports, and earnings notes.
No research on PRNAF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRNAF report →Similar companies
Peers in the same neighborhood.
AI analysis · Last refreshed June 28, 2026 · Live quote · Not investment advice